ADVFN Logo ADVFN

No pudimos encontrar ningún resultado para:
Asegúrate de que la ortografía sea correcta o intenta ampliar tu búsqueda.

Tendencias Ahora

Listas Principales

Parece que no has iniciado sesión.
Haz clic en el botón de abajo para iniciar sesión y ver tu historial reciente.

Hot Features

Registration Strip Icon for monitor Monitoree múltiples cotizaciones en tiempo real de los principales intercambios, como la Bolsa de Valores de Londres, NASDAQ, NYSE, AMEX, Bovespa y más.

ARDS Aridis Pharmaceuticals Inc

0.289
0.00 (0.00%)
01 May 2024 - Cerrado
Retrasado por 15 minutos
Nombre de la Acción Símbolo de la Acción Bolsa de Valores Tipo de Valor
Aridis Pharmaceuticals Inc ARDS NASDAQ Acción Común
  Variación del Día (ptos.) Variación del Día (%) Último Precio Hora
0.00 0.00% 0.289 19:00:00
Precio de Apertura Precio Mínimo Precio Máximo Precio de cierre Precio Anterior
0.289 0.289
más cotizaciones de acciones »

Noticias Recientes

Fecha Hora Fuente Noticia
13/2/202419:02EDGAR2Form SC 13G/A - Statement of acquisition of beneficial..
16/1/202405:05EDGAR2Form 8-K - Current report
15/12/202315:15GLOBEAridis Pharmaceuticals Announces Adjournment of Annual..
03/11/202316:00EDGAR2Form 8-K - Current report
03/11/202315:15GLOBEAridis Pharmaceuticals Announces Third Quarter 2023..
03/11/202305:15EDGAR2Form DEFA14A - Additional definitive proxy soliciting..
13/9/202320:47EDGAR2Form 10-Q - Quarterly report [Sections 13 or 15(d)]
07/9/202315:15EDGAR2Form 8-K - Current report
25/8/202315:05EDGAR2Form 8-K - Current report
04/8/202315:05EDGAR2Form 424B5 - Prospectus [Rule 424(b)(5)]
03/8/202315:15EDGAR2Form 424B5 - Prospectus [Rule 424(b)(5)]
02/8/202307:17GLOBEAridis Pharmaceuticals Announces $2 Million Offering
01/8/202323:15EDGAR2Form EFFECT - Notice of Effectiveness
21/7/202305:49EDGAR2Form S-1/A - General form for registration of securities..
20/7/202316:18EDGAR2Form 8-K - Current report
17/7/202315:05GLOBEAridis Receives Agreement from the European Medicines Agency..
17/7/202314:01EDGAR2Form S-1/A - General form for registration of securities..
17/7/202306:36EDGAR2Form S-1/A - General form for registration of securities..
12/7/202307:00GLOBEAridis’ AR-301 Monoclonal Antibody is Among the First..
20/6/202307:00GLOBEAridis Pharmaceuticals' AR-301 Eligible for Consideration..
08/6/202315:05GLOBEAridis Pharmaceuticals Announces First Quarter 2023..
31/5/202307:00GLOBEAridis Receives Agreement from the FDA on a Single..
25/5/202315:05GLOBEAridis Pharmaceuticals Receives Nasdaq Notice on Late Filing..

Su Consulta Reciente

Delayed Upgrade Clock